Mark Lewis: Myriam Chalabi reporting the NICHE-2 trial in NEJM

Mark Lewis shared on X:                 .

“TLC: don’t go chasing waterfalls

Myriam Chalabi reporting the NICHE-2 trial with 95% of locally advanced, mismatch repair-deficient colon cancer responding (pathologically!) to neoadjuvant immunotherapy in NEJM.”

Source: Mark Lewis/X

Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.